MEKanistic Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$5M
- Investors
-
2
MEKanistic Therapeutics General Information
Description
Operator of a biotechnology company intended to develop cancer therapeutics. The company uses computational tools to design medications used to block key pathways to signal cancer cell growth, enabling patients to access multi-compound treatments.
Contact Information
Website
www.mekanistic.comCorporate Office
- 1015 Glenwood Avenue
- Fourth Floor
- Minneapolis, MN 55405
- United States
Corporate Office
- 1015 Glenwood Avenue
- Fourth Floor
- Minneapolis, MN 55405
- United States
MEKanistic Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series A) | 02-Jun-2022 | $5M | Completed | Pre-Clinical Trials | ||
| 4. Grant | 01-Sep-2021 | Completed | Startup | |||
| 3. Early Stage VC | 12-Mar-2019 | Completed | Startup | |||
| 2. Grant | 01-Feb-2017 | $275K | Completed | Startup | ||
| 1. Accelerator/Incubator | 01-Jan-2017 | Completed | Startup |
MEKanistic Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
MEKanistic Therapeutics Patents
MEKanistic Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230133958-A1 | Compounds useful in modulating egfr and pi3k | Inactive | 20-Oct-2021 | ||
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors | Active | 22-Dec-2020 | ||
| US-20220213054-A1 | Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors | Active | 22-Dec-2020 | ||
| US-20240239764-A1 | Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors | Pending | 22-Dec-2020 | C07D401/04 |
MEKanistic Therapeutics Signals
MEKanistic Therapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Invenshure | Accelerator/Incubator | Minority | ||
| U.S. Department of Health and Human Services | Government |
MEKanistic Therapeutics FAQs
-
When was MEKanistic Therapeutics founded?
MEKanistic Therapeutics was founded in 2015.
-
Where is MEKanistic Therapeutics headquartered?
MEKanistic Therapeutics is headquartered in Minneapolis, MN.
-
What is the size of MEKanistic Therapeutics?
MEKanistic Therapeutics has 7 total employees.
-
What industry is MEKanistic Therapeutics in?
MEKanistic Therapeutics’s primary industry is Drug Discovery.
-
Is MEKanistic Therapeutics a private or public company?
MEKanistic Therapeutics is a Private company.
-
What is the current valuation of MEKanistic Therapeutics?
The current valuation of MEKanistic Therapeutics is .
-
What is MEKanistic Therapeutics’s current revenue?
The current revenue for MEKanistic Therapeutics is .
-
How much funding has MEKanistic Therapeutics raised over time?
MEKanistic Therapeutics has raised $6.86M.
-
Who are MEKanistic Therapeutics’s investors?
Invenshure and U.S. Department of Health and Human Services have invested in MEKanistic Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process